Asuragen Myotonic Dystrophy 1 Dx Kit Receives CE Mark

Dec 04, 2018

|

NEW YORK (GenomeWeb) — Asuragen said today that it has received CE marking for its AmplideX DM1 Dx kit for use in the diagnosis of myotonic dystrophy type I (DM1).

DM1, also known as Steinert's disease, is an inherited form of muscular dystrophy characterized by a repeat expansion of 50 CTG trinucleotides or greater in the DMPK gene. According to Asuragen, disease severity positively correlated to the number of repeats, which can extend beyond 1,000.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Breaking News

Featured White Papers

For In Vitro Diagnostic Materials: Efficacy vs. Thimerosal and Sodium Azide

Development of a Quantitative Lateral Flow Test Using Estapor Europium Microspheres

Performance of Estapor Microspheres and Hi-Flow Plus Membranes in a Lateral Flow Assay for Human Chorionic Gonadotropin (hCG)

ProClin 300 Preservative: An In-Depth Technical Analysis

Apr

16

Featured Webinar

The Post-Vaccine COVID Testing Landscape: A Virtual Roundtable Discussion

With COVID-19 vaccines rolling out, clinical labs and test developers are preparing for changes in both demand for testing and types of testing for SARS-CoV-2.

Apr

29

Featured Webinar

A New Generation of PCR: At-home Testing and Preparing for Emerging Strains of COVID-19

Join Dr. Heather Fehling, Chief Scientific Officer at Clinical Reference Labs (CRL), as she provides some insights regarding the future applications of PCR testing.

May

13

Featured Webinar

Limits of Detection Matter: New Challenges for SARS-CoV-2 Diagnostics and COVID-19 Patient Management

As we pass the one-year anniversary of both the COVID-19 pandemic and the first Emergency Use Authorized SARS-CoV-2 PCR detection assays, there remains significant opportunity for clinical laboratories to advance testing and support improved patient management.

May

18

Featured Webinar

Put Your Money Where Your Mouth Is: Tracking and Attacking COVID-19 through State-Wide Saliva Surveillance

This webinar will present the details of a COVID-19 saliva screening program that has been implemented at more than 90 different colleges, universities, private schools, and nursing homes across New York state.

Menu

Asuragen Myotonic Dystrophy 1 Dx Kit Receives CE Mark

To read the full story....

Breaking News

GenScript Biotech, IES Diagnostics Partner to Distribute SARS-CoV-2 Antibody Kit

NantHealth Lands $137.5M in Financing to Extend Debt Maturity Date

RenalytixAI, Joslin Diabetes Center Ink Kidney Disease IP Agreement

Calciscon Raises $2.7M in Series A Round

PerkinElmer Preliminary Q1 Revenues Grow 98 Percent; FDA Issues EUA for PCR COVID-19 Test

Cofactor Genomics Begins Multi-Site Clinical Trial for Immunotherapy Prediction Assay

Featured White Papers

The Post-Vaccine COVID Testing Landscape: A Virtual Roundtable Discussion

A New Generation of PCR: At-home Testing and Preparing for Emerging Strains of COVID-19

Limits of Detection Matter: New Challenges for SARS-CoV-2 Diagnostics and COVID-19 Patient Management

Put Your Money Where Your Mouth Is: Tracking and Attacking COVID-19 through State-Wide Saliva Surveillance

What's Popular?

With Luminex Acquisition, DiaSorin to Broaden MDx Portfolio, Expand US Presence

PerkinElmer Preliminary Q1 Revenues Grow 98 Percent; FDA Issues EUA for PCR COVID-19 Test

FDA-Led Group Evaluates Performance of RUO Liquid Biopsy Assays to Inform Practice Guidelines

Labs Craft SARS-CoV-2 Variant Genotyping Assays for Screening, Surveillance

Thermo Fisher Scientific Gets FDA EUA for High-Throughput, Automated COVID-19 Test Kit

Sponsorships